Abstracts tagged "Outcome measures"

Abstract Number: 0514 • ACR Convergence 2020
Feasibility of 18F-fluorodeoxyglucose Positron Emission Tomography to Monitor the Effect of Tocilizumab on Vascular Inflammation in Giant Cell Arteritis: A Prospective Observational Cohort Study
Kaitlin Quinn¹, Himanshu Dashora², Mark Ahlman³, Elaine Novakovich² and Peter C. Grayson², ¹Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, ²Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, MD, ³National Institutes of Health, Clinical Center, Radiology and Imaging Sciences, Bethesda, MD
Background/Purpose: Two randomized controlled trials have demonstrated the clinical efficacy of tocilizumab for treatment of giant cell arteritis (GCA) (1,2). In these trials, response to…
Abstract Number: 0909 • ACR Convergence 2020
Residual Disease Activity in Psoriatic Arthritis Patients Treated with Secukinumab and Adalimumab Who Achieved Remission or Low Disease Activity: Results from a Phase 3b, Randomized, Double-blinded, Active-controlled, Head-to-head Study
Iain McInnes¹, Philip Mease², Dafna Gladman³, Laura Coates⁴, Peter Nash⁵, Alexis Ogdie⁶, Frank Behrens⁷, Philippe Goupille⁸, Arthur Kavanaugh⁹, Ruvie Martin¹⁰, Erhard Quebe-Fehling¹¹ and Corine Gaillez¹¹, ¹Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, ²Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ³Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁴University of Oxford, Oxford, United Kingdom, ⁵School of Medicine Griffith University, Brisbane, Queensland, Australia, ⁶University of Pennsylvania, Philadelphia, PA, ⁷CIRI/Rheumatology & Fraunhofer IME, Research Division Translational Medicine and Pharmacology, Goethe University Hospital, Frankfurt, Hessen, Germany, ⁸CHU Tours, department of rheumatology, Tours, France, ⁹Division of Rheumatology, Allergy, & Immunology, University of California San Diego Medical School, San Diego, CA, ¹⁰Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹¹Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Recent EULAR recommendations propose that treatment of psoriatic arthritis (PsA) should seek remission (REM) or alternatively low disease activity (LDA) by regular disease activity…
Abstract Number: 1585 • ACR Convergence 2020
Lessons Learned Through Rapid Quality Improvement for Telehealth Implementation in an Academic Rheumatology Practice During the COVID-19 Pandemic
Julie Thomas¹, Dorota Lebiedz-Odrobina¹, Kyle Register¹, Francesca Ferrara¹, Danielle Barlow¹, Alicia Riddle¹ and Karla Miller², ¹University of Utah, Salt Lake City, UT, ²Veterans Affairs Salt Lake City Health Care System, Salt Lake City, UT
Background/Purpose: The COVID-19 pandemic created an urgent need for access to care while preserving patient safety through social distancing. Prior to the pandemic, patients were…
Abstract Number: 1743 • ACR Convergence 2020
Perioperative Steroids in Rheumatoid Arthritis Patients Having Total Joint Replacements: Help or Harm?
Tariq Chukir¹, Susan Goodman², Haley Tornberg³, Huong Do⁴, Charlene Thomas⁵, Alana Sigmund³, Peter Sculco⁶, Bella Mehta⁶, Linda Russell⁶, Mark Figgie² and Emily Stein⁷, ¹Weill Cornell Medicine and New York Presbyterian Hospital, New York, ²Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ³Hospital for Special Surgery, New York, ⁴Hospital for Special Surgery, New York, NY, ⁵Weill Cornell Medicine, New York, ⁶Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ⁷Endocrine Service, Hospital for special surgery, Department of Medicine, Weill Cornell Medical College, New York, NY
Background/Purpose: Optimal perioperative glucocorticoids (GC) dosing for rheumatoid arthritis (RA) patients on chronic GCs undergoing total joint replacement is unknown. Ideal GC dosing prevents perioperative…
Abstract Number: 0263 • ACR Convergence 2020
Factors Associated with Disease Activity Remission and Recurrence in Cutaneous Lupus Erythematosus
Stephanie Florez-Pollack¹, Syed Rizvi², Benjamin Chong² and Linda Hynan², ¹University of Pennsylvania, PHILADELPHIA, PA, ²University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Cutaneous lupus erythematosus (CLE) is a photosensitive skin disorder that can occur with systemic lupus erythematosus. As CLE often fluctuates in disease activity, little…
Abstract Number: 0518 • ACR Convergence 2020
The Impact of Large Vessel Vasculitis of the Axillary Artery on Cumulative Glucocorticoid Dose and Relapse Rate in Giant Cell Arteritis
Philipp Bosch¹, Christian Dejaco², Wolfgang Schmidt³, Andreas Krause³, Kenny-Davis Schlüter³, Gudrun Pregartner⁴ and Valentin Schaefer⁵, ¹Department of Rheumatology and Immunology, Medical University Graz, Graz, Austria, Graz, Austria, ²Department of Rheumatology and Immunology, Medical University Graz, Graz, Austria and Rheumatology Service, Hospital of Bruneck, Bruneck, Italy, Bruneck, Italy, ³Immanuel Krankenhaus Berlin, Medical Center for Rheumatology Berlin-Buch, Berlin, Germany, ⁴Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria, Graz, Austria, ⁵Clinic of Internal Medicine III, Department of Oncology, Hematology and Rheumatology, University Hospital Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany
Background/Purpose: Prognostic markers for clinical outcomes in giant cell arteritis (GCA) are urgently needed. While large vessel GCA (LV-GCA) has been associated with higher glucocorticoid…
Abstract Number: 0941 • ACR Convergence 2020
MDHAQ/RAPID3 (multidimensional Health Assessment Questionnaire/routine Assessment of Patient Index Data) Levels Are Elevated in Rheumatology Patients Who Meet 2011 Fibromyalgia (FM) or MDHAQ/FAST3 (fibromyalgia Assessment Screening Tool) Criteria
Juan Schmukler¹, Tengfei Li², Kyle Schroeder³ and Theodore Pincus³, ¹Mount Sinai Hospital Chicago, IL, Chicag, IL, ²Georgetown University, Washigton, ³Rush University Medical Center, Chicago, IL
Background/Purpose: RAPID3 (routine assessment of patient index data) on an MDHAQ (multiple multidimensional health assessment questionnaire) was developed initially to assess patients with rheumatoid arthritis…
Abstract Number: 1596 • ACR Convergence 2020
Coproduction of Care for Veterans with RA: Improving Elicitation and Documentation of Patient Goals
Swathi Reddy¹, Kyawt Shwin¹, Rashmi Arora¹, Sarah Homann², Lisa Johnson³, Yusuf Chao⁴, Aricca Van Citters³, Brant Oliver⁵, Guy Eakin⁶, Eugene Nelson³, Andreas Reimold¹ and Salahuddin Kazi¹, ¹Veterans Affairs North Texas Healthcare System / UT Southwestern Medical Center, Dallas, TX, ²Veterans Affairs Tennessee Valley Healthcare System / Vanderbilt University Medical Center, Nashville, TN, ³The Dartmouth Institute for Health Policy & Clinical Practice, Lebanon, NH, ⁴UT Southwestern Medical Center, Dallas, TX, ⁵The Dartmouth Institute for Health Policy & Clinical Practice / Veterans Affairs National Quality Scholars Fellowship in Healthcare Quality & Safety, Lebanon, NH, ⁶Arthritis Foundation, Atlanta, GA
Background/Purpose: Coproduction of healthcare services offers a pathway to increase patient engagement in care. Patients and clinicians coproduce care by working together to: (1) co-assess…
Abstract Number: 1851 • ACR Convergence 2020
Different Disease Activity Trajectories in Early Axial Spondyloarthritis Lead to Significantly Different Long-term Outcomes : A Cluster-based Analysis of the DESIR Cohort
Benattar Leslie¹, Anna Molto², Laure Gossec³ and Resche Rigon Matthieu⁴, ¹Cochin Hospital, Paris, Paris, Ile-de-France, France, ²Rheumatology Department, Cochin Hospital, APHP, Paris, France, Paris, France, ³Sorbonne University, INSERM; Pitié-Salpêtrière Hospital, Paris, Ile-de-France, France, ⁴INSERM (UFR 1153), Saint Louis Hospital, Paris, Paris, France
Background/Purpose: AxSpA is a heterogeneous disease, leading to different treatment and follow-up modalities depending on the presentation, along with other elements (socio-economic, gender, etc..). In a…
Abstract Number: 0271 • ACR Convergence 2020
External Validation of the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI) as a Predictor of Mortality and Organ Damage Accrual in Systemic Lupus Erythematosus
Alicia Malone¹, Alexandra Legge¹ and John Hanly¹, ¹Dalhousie University, Halifax, NS, Canada
Background/Purpose: Using data from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort, a frailty index (FI) was recently developed as a measure of susceptibility…
Abstract Number: 0542 • ACR Convergence 2020
Examining the Long-Term and Short-Term Day-To-Day Pain Variability in Inflammatory and Non-Inflammatory Rheumatic and Musculoskeletal Diseases Using Multilevel and Markov Transition Models: Cloudy with a Chance of Pain, a National U.K. Smartphone Study
Huai Leng Pisaniello¹, Mark Lunt², John McBeth³ and William Dixon², ¹University of Adelaide, Kidman Park, South Australia, Australia, ²Centre for Epidemiology Versus Arthritis, University of Manchester, Manchester, United Kingdom, ³University of Manchester, Manchester, United Kingdom
Background/Purpose: Chronic pain is common in rheumatic and musculoskeletal diseases (RMDs), yet the patterns and the extent of variability over time are poorly understood. Real-time…
Abstract Number: 0987 • ACR Convergence 2020
Efficacy and Safety of Iberdomide in Patients with Active Systemic Lupus Erythematosus: 24-Week Results of a Phase 2, Randomized, Placebo-Controlled Study
Joan Merrill¹, Victoria Werth², Richard Furie³, Ronald van Vollenhoven⁴, Milan Petronijevic⁵, Benito Velasco Zamora⁶, Maria Majdan⁷, Fedra Irazoque-Palazuelos⁸, Michael Weiswasser⁹, Shimon Korish⁹, Peter Schafer⁹, Zhaohui Liu⁹, Allison Gaudy⁹, Nataliya Agafonova⁹ and Nikolay Delev⁹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA, ³Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ⁴Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁵Military Medical Academy, Belgrade, Serbia, ⁶Instituto CER S.A., Buenos Aires, Argentina, ⁷Medical University of Lublin and Samodzielny Publicnzy Szpital Kliniczny Nr 4 w Lublinie, Lublin, Poland, ⁸Centro de Investigación y Tratamiento Reumatológico S.C, Miguel Hidalgo, Mexico, ⁹Bristol Myers Squibb, Princeton
Background/Purpose: Iberdomide is a high-affinity cereblon ligand that promotes ubiquitination and proteasomal degradation of Ikaros (IKZF1) and Aiolos (IKZF3), transcription factors linked to the genetic…
Abstract Number: 1616 • ACR Convergence 2020
Systematic Review of Effectiveness Outcomes Reported in Rheumatology Transition Literature
Heather Bannerman¹, Karen Beattie¹, Avanti Patel², Milica Tanic², Michelle Batthish³ and Mark Matsos², ¹McMaster University, Hamilton, ON, Canada, ²McMaster University, Hamilton, Canada, ³McMaster Children's Hospital, Hamilton, ON, Canada
Background/Purpose: In young patients with rheumatologic disease, transition from pediatric to adult care is a complex process. Poor transitional care leads to health deterioration, loss…
Abstract Number: 1873 • ACR Convergence 2020
The Changing Profile of Ankylosing Spondylitis in the Biologic Era
Lauren Ridley¹, Michael Weisman², Lianne Gensler³, Michael Ward⁴, Mark Hwang⁵, Amirali Tahanan⁶, MinJae Lee⁷, Mohammad Rahbar⁶, Mariko Ishimori⁸, Matthew Brown⁹ and John Reveille¹⁰, ¹McGovern Medical School at UTHealth, Houston, TX, ²Cedars Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, ³University of California San Francisco, San Francisco, CA, ⁴National Institutes of Health, Bethesda, MD, ⁵McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, ⁶McGovern Medical School at UTHealth, Houston, ⁷UT Southwestern, Dallas, ⁸Cedars-Sinai Medical Center, Los Angeles, CA, ⁹Guy's and St Thomas, NHS Foundation Trust and King's College London NIHR Biomedical Research Centre, King's College London, London, United Kingdom, London, United Kingdom, ¹⁰Department of Internal Medicine, University of Texas, Houston, TX
Background/Purpose: To compare disease characteristics, comorbidities, and medication utilization of 573 patients with ankylosing spondylitis (AS) with short (< 20 years) disease duration (from symptom…
Abstract Number: 0018 • ACR Convergence 2020
PROMIS-29 and Health Related Quality of Life in Rheumatology Outpatients During the COVID-19 Pandemic in New York City
Gregory Vitone¹, Marianna Frey², Candace Feldman³, Lindsay Lally², Anne Bass⁴, Jane Salmon², Mary Crow², Michael Lockshin⁵, Vivian Bykerk², Medha Barbhaiya⁵ and Lisa Mandl², ¹Hospital for Special Surgery, New York, ²Hospital for Special Surgery, New York, NY, ³Brigham and Women's Hospital, Boston, MA, ⁴Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ⁵Hospital for Special Surgery, Barbara Volcker Center for Women and Rheumatic Diseases, New York, NY
Background/Purpose: Little is known about the general health and wellbeing of patients with systemic rheumatic diseases (SRD) during the COVID pandemic. We sought to compare…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.